Tag Archives: Failed

AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial

AstraZeneca felt the blow last month when Mystic, a key trial examining its immuno-oncology drug Imfinzi in previously untreated lung cancer, failed. But now that the dust has settled, the company is looking for bright spots in the miss. As executives were quick to point out, there was “clear clinical benefit” of Imfinzi monotherapy compared… Read More »